ArticleOncotarget2020

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.

Tomoya Aikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.